Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+operable breast cancer: 5-year outcomes of NSABP protocol B-41.

被引：17

作者：

Robidoux, Andre

Tang, Gong

Rastogi, Priya

Geyer, Charles E.

Azar, Catherine A.

Atkins, James Norman

Fehrenbacher, Louis

Bear, Harry Douglas

Baez-Diaz, Luis

Sarwar, Shakir

Margolese, Richard G.

Farrar, William Blair

Brufsky, Adam M.

Shibata, Henry R.

Bandos, Hanna

Paik, Soonmyung

Costantino, Joseph P.

Swain, Sandra M.

Mamounas, Eleftherios P.

Wolmark, Norman

机构：

[1] NSABP NRG Oncol, Montreal, PQ, Canada

[2] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[3] NRG Oncol, Pittsburgh, PA USA

[4] Univ Pittsburgh, Pittsburgh, PA USA

[5] NSABP NRG Oncol, Pittsburgh, PA USA

[6] Univ Pittsburgh Med Canc Ctr, Magee Womens Hosp, Pittsburgh, PA USA

[7] Virginia Commonwealth Univ, Massey Canc Ctr, Pittsburgh, PA USA

[8] NSABP NRG Oncol, Green Valley, AZ USA

[9] Kaiser Permanente, Green Valley, AZ USA

[10] NSABP NRG Oncol, Goldsboro, NC USA

[11] Southeastern Med Oncol Ctr, Goldsboro, NC USA

[12] NSABP NRG Oncol, Novato, CA USA

[13] Kaiser Permanente Northern Calif, Novato, CA USA

[14] NRG Oncol, Richmond, VA USA

[15] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA USA

[16] NSABP NRG Oncol, San Juan, PR USA

[17] San Juan CCOP, San Juan, PR USA

[18] NSABP NRG Oncol, Columbus, OH USA

[19] Columbus NCORP Grant Med Ctr, Columbus, OH USA

[20] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[21] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA

[22] UPMC, Magee Womens Hosp, Pittsburgh, PA USA

[23] McGill Univ Hlth Ctr, Royal Victoria Hosp, Montreal, PQ, Canada

[24] Severance BioMed Sci Inst, Pittsburgh, PA USA

[25] Yonsei Univ, Coll Med, Pittsburgh, PA USA

[26] NSABP NRG Oncol, Washington, DC USA

[27] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA

[28] NSABP NRG Oncol, Orlando, FL USA

[29] Orlando Hlth, UF Canc Ctr, Orlando, FL USA

[30] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.501

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

501

引用

页数：2

共 36 条

[21] Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients
Abdel-Razeq, Hikmat
Saadeh, Salwa S.
Abu-Nasser, Mahmoud
Abdulelah, Hazem
Marie, Lina
Salam, Murad
Ali, Basel Al-Haj
Ibrahim, Mohammad
Rimawi, Dalia
ONCOTARGETS AND THERAPY, 2018, 11 : 2091 - 2096
[22] Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
Stefanie de Groot
Hanno Pijl
Ayoub Charehbili
Saskia van de Ven
Vincent T. H. B. M. Smit
Elma Meershoek-Klein Kranenbarg
Joan B. Heijns
Laurence J. C. van Warmerdam
Lonneke W. Kessels
M. Wouter Dercksen
Manon J. A. E. Pepels
Hanneke W. M. van Laarhoven
Birgit E. P. J. Vriens
Hein Putter
Marta Fiocco
Gerrit-Jan Liefers
Jacobus J. M. van der Hoeven
Johan W. R. Nortier
Judith R. Kroep
Breast Cancer Research, 21
[23] Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
Coudert, Bruno
Pierga, Jean-Yves
Mouret-Reynier, Marie-Ange
Kerrou, Kaldoun
Ferrero, Jean-Marc
Petit, Thierry
Le Du, Fanny
Dupre, Pierre-Francois
Bachelot, Thomas
Gabelle, Philippe
Chauvet, Marie-Pierre
Coeffic, David
Barbe, Catherine
Prevost, Jean-Briac
Paintaud, Gilles
Thibault, Gilles
Ferhat, Abdennour
Dupin, Julien
Berriolo-Riedinger, Alina
Arnould, Laurent
ECLINICALMEDICINE, 2020, 28
[24] Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
de Groot, Stefanie
Pijl, Hanno
Charehbili, Ayoub
van de Ven, Saskia
Smit, Vincent T. H. B. M.
Meershoek-Klein Kranenbarg, Elma
Heijns, Joan B.
van Warmerdam, Laurence J. C.
Kessels, Lonneke W.
Dercksen, M. Wouter
Pepels, Manon J. A. E.
van Laarhoven, Hanneke W. M.
Vriens, Birgit E. P. J.
Putter, Hein
Fiocco, Marta
Liefers, Gerrit-Jan
van der Hoeven, Jacobus J. M.
Nortier, Johan W. R.
Kroep, Judith R.
BREAST CANCER RESEARCH, 2019, 21 (01)
[25] 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Gianni, Luca
Pienkowski, Tadeusz
Im, Young-Hyuck
Tseng, Ling-Ming
Liu, Mei-Ching
Lluch, Ana
Staroslawska, Elzbieta
de la Haba-Rodriguez, Juan
Im, Seock-Ah
Pedrini, Jose Luiz
Poirier, Brigitte
Morandi, Paolo
Semiglazov, Vladimir
Srimuninnimit, Vichien
Bianchi, Giulia Valeria
Magazzu, Domenico
McNally, Virginia
Douthwaite, Hannah
Ross, Graham
Valagussa, Pinuccia
LANCET ONCOLOGY, 2016, 17 (06): : 791 - 800
[26] Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes
Andre, V.
Harbeck, N.
Rastogi, P.
O'Shaughnessy, J.
Boyle, F.
Cortes, J.
Rugo, H. S.
Goetz, M. P.
Hamilton, E.
Huang, C. -s.
Senkus, E.
Tryakin, A.
Neven, P.
Huober, J.
Wei, R.
Munoz, M.
Antonio, B. S.
Shahir, A.
Martin, M.
Johnston, S.
BREAST, 2025, 80
[27] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
Reinisch, Mattea
Harbeck, Nadia
Rastogi, Priya
O'shaughnessy, Joyce
Boyle, Frances
Cortes, Javier
Rugo, Hope S.
Hamilton, Erika
Goetz, Matthew P.
Huang, Chiun-Sheng
Senkus, Elzbieta
Trakin, Alexey
Neven, Patrick
Huober, Jens
Ran, Wei
Andre, Valerie
Munoz-Fernandez, Maria
Antonio, Belen San
Shahir, Ashwin
Martin, Miguel
Johnston, Stephen
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 227 - 228
[28] Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
Harbeck, N.
Rastogi, P.
O'Shaughnessy, J.
Boyle, F.
Cortes, J.
Rugo, H. S.
Goetz, M. P.
Hamilton, E. P.
Huang, C.
Senkus-Konefka, E.
Tryakin, A.
Neven, P.
Huober, J.
Wei, R. J.
Andre, V.
Munoz, M.
Antonio, B. San
Shahir, A.
Jimenez, M. Martin
Johnston, S. R. D.
ANNALS OF ONCOLOGY, 2023, 34 : S1256 - S1256
[29] De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR1/HER21 Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial
Harbeck, Nadia
Nitz, Ulrike A.
Christgen, Matthias
Kuemmel, Sherko
Braun, Michael
Schumacher, Claudia
Potenberg, Jochem
Tio, Joke
Aktas, Bahriye
Forstbauer, Helmut
Grischke, Eva-Maria
Scheffen, Iris
Malter, Wolfram
von Schumann, Raquel
Just, Marianne
zu Eulenburg, Christine
Biehl, Claudia
Kolberg-Liedtke, Cornelia
Deurloo, Regula
de Haas, Sanne
Jozwiak, Katarzyna
Hauptmann, Michael
Kates, Ronald
Graeser, Monika
Wuerstlein, Rachel
Kreipe, Hans H.
Gluz, Oleg
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3796 - +
[30] Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching
Fujita, Noriko
Fujita, Koichi
Kim, Seung Jin
Iguchi, Chikage
Nomura, Takashi
Aono, Toyokazu
Yanagisawa, Tetsu
Enomoto, Yukie
Inakami, Keiko
Miyagawa, Yoshimasa
Tomoike, Riki
Kasugai, Tsutomu
Shiba, Eiichi
ONCOLOGY, 2022, 100 (05) : 257 - 266

← 1 2 3 4 →